| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Analysis of the coding genome of diffuse large B-cell lymphoma.
|
Nat Genet
|
2011
|
6.06
|
|
2
|
Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
|
Nature
|
2011
|
5.20
|
|
3
|
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.
|
J Exp Med
|
2011
|
4.37
|
|
4
|
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
|
Blood
|
2010
|
2.84
|
|
5
|
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
|
J Natl Cancer Inst
|
2002
|
2.38
|
|
6
|
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
|
Blood
|
2011
|
2.37
|
|
7
|
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
|
Blood
|
2009
|
2.36
|
|
8
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
|
J Clin Oncol
|
2010
|
2.27
|
|
9
|
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2014
|
1.92
|
|
10
|
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.
|
Haematologica
|
2011
|
1.67
|
|
11
|
Simian virus 40 infection in lymphoproliferative disorders.
|
Lancet
|
2003
|
1.63
|
|
12
|
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
|
Clin Cancer Res
|
2010
|
1.62
|
|
13
|
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.
|
Blood
|
2010
|
1.60
|
|
14
|
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
|
Blood
|
2013
|
1.55
|
|
15
|
Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis.
|
Haematologica
|
2008
|
1.54
|
|
16
|
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2012
|
1.51
|
|
17
|
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
|
Leuk Lymphoma
|
2013
|
1.47
|
|
18
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
|
J Clin Oncol
|
2014
|
1.44
|
|
19
|
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
|
Cancer Res
|
2009
|
1.34
|
|
20
|
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
|
J Clin Oncol
|
2011
|
1.32
|
|
21
|
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
|
Am J Hematol
|
2011
|
1.27
|
|
22
|
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
|
Haematologica
|
2013
|
1.26
|
|
23
|
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
|
Haematologica
|
2013
|
1.21
|
|
24
|
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.
|
Blood
|
2003
|
1.19
|
|
25
|
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.
|
Cancer
|
2011
|
1.18
|
|
26
|
Clinical implications of the molecular genetics of chronic lymphocytic leukemia.
|
Haematologica
|
2013
|
1.17
|
|
27
|
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.
|
Haematologica
|
2010
|
1.17
|
|
28
|
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
|
N Engl J Med
|
2015
|
1.15
|
|
29
|
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
|
Cancer Res
|
2011
|
1.13
|
|
30
|
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
|
Br J Haematol
|
2008
|
1.12
|
|
31
|
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.
|
Br J Haematol
|
2008
|
1.12
|
|
32
|
Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.
|
Hematol Oncol
|
2005
|
1.11
|
|
33
|
Molecular histogenesis of plasmablastic lymphoma of the oral cavity.
|
Br J Haematol
|
2002
|
1.10
|
|
34
|
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
|
Blood
|
2011
|
1.09
|
|
35
|
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
|
Blood
|
2014
|
1.09
|
|
36
|
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.
|
Blood
|
2013
|
1.06
|
|
37
|
Molecular histogenesis of posttransplantation lymphoproliferative disorders.
|
Blood
|
2003
|
1.03
|
|
38
|
Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma.
|
Cancer Res
|
2002
|
1.03
|
|
39
|
Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
|
Hematol Oncol
|
2012
|
1.01
|
|
40
|
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
|
Br J Haematol
|
2014
|
1.00
|
|
41
|
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia.
|
Br J Haematol
|
2008
|
0.98
|
|
42
|
A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays.
|
Transfusion
|
2010
|
0.97
|
|
43
|
Genome wide DNA-profiling of HIV-related B-cell lymphomas.
|
Br J Haematol
|
2009
|
0.97
|
|
44
|
Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis.
|
Haematologica
|
2011
|
0.97
|
|
45
|
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk.
|
Br J Haematol
|
2011
|
0.97
|
|
46
|
Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
|
Br J Haematol
|
2008
|
0.96
|
|
47
|
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
|
Br J Haematol
|
2004
|
0.96
|
|
48
|
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.
|
Hematol Oncol
|
2010
|
0.95
|
|
49
|
Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience.
|
Crit Rev Oncol Hematol
|
2010
|
0.94
|
|
50
|
Inherited genetic susceptibility to monoclonal B-cell lymphocytosis.
|
Blood
|
2010
|
0.94
|
|
51
|
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?
|
Blood
|
2008
|
0.94
|
|
52
|
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features.
|
Br J Haematol
|
2014
|
0.93
|
|
53
|
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
|
Br J Haematol
|
2012
|
0.93
|
|
54
|
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.
|
Genes Chromosomes Cancer
|
2011
|
0.93
|
|
55
|
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
|
Clin Cancer Res
|
2013
|
0.92
|
|
56
|
CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells.
|
Clin Cancer Res
|
2004
|
0.92
|
|
57
|
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia.
|
Haematologica
|
2008
|
0.91
|
|
58
|
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
|
Blood
|
2011
|
0.91
|
|
59
|
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.
|
Br J Haematol
|
2011
|
0.89
|
|
60
|
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
|
Blood
|
2013
|
0.89
|
|
61
|
Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas.
|
Br J Haematol
|
2006
|
0.89
|
|
62
|
Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.
|
Hematol Oncol
|
2012
|
0.88
|
|
63
|
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
|
Clin Cancer Res
|
2009
|
0.88
|
|
64
|
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
|
Haematologica
|
2010
|
0.88
|
|
65
|
Glucose-modulated mitochondria adaptation in tumor cells: a focus on ATP synthase and inhibitor Factor 1.
|
Int J Mol Sci
|
2012
|
0.87
|
|
66
|
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
|
Haematologica
|
2014
|
0.87
|
|
67
|
'Everybody knows', but the rest of the world: the case of a caterpillar-borne reproductive loss syndrome in dromedary camels observed by Sahrawi pastoralists of Western Sahara.
|
J Ethnobiol Ethnomed
|
2013
|
0.87
|
|
68
|
Thyroid lymphoma: beyond antigen stimulation.
|
Leuk Res
|
2009
|
0.86
|
|
69
|
Predictive markers and driving factors behind Richter syndrome development.
|
Expert Rev Anticancer Ther
|
2011
|
0.86
|
|
70
|
Lateralization of dichotic speech stimuli is based on specific auditory pathway interactions: neuromagnetic evidence.
|
Cereb Cortex
|
2006
|
0.86
|
|
71
|
ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.
|
Haematologica
|
2012
|
0.86
|
|
72
|
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
|
J Transl Med
|
2010
|
0.86
|
|
73
|
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.
|
Hematol Oncol
|
2010
|
0.85
|
|
74
|
Blood pressure assessment in haemodialysis patients: comparison between pre-dialysis blood pressure and ambulatory blood pressure measurement.
|
Nephrology (Carlton)
|
2009
|
0.85
|
|
75
|
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism.
|
Haematologica
|
2013
|
0.85
|
|
76
|
Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
|
J Pathol
|
2009
|
0.84
|
|
77
|
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma.
|
Br J Haematol
|
2010
|
0.83
|
|
78
|
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2012
|
0.83
|
|
79
|
Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia.
|
Blood
|
2008
|
0.83
|
|
80
|
Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity.
|
Hum Pathol
|
2002
|
0.82
|
|
81
|
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
|
Haematologica
|
2013
|
0.82
|
|
82
|
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
|
Ann Hematol
|
2014
|
0.82
|
|
83
|
Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.
|
Haematologica
|
2011
|
0.82
|
|
84
|
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array.
|
Br J Haematol
|
2011
|
0.81
|
|
85
|
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution.
|
Transplantation
|
2006
|
0.81
|
|
86
|
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
|
J Transl Med
|
2012
|
0.81
|
|
87
|
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
|
Am J Hematol
|
2014
|
0.81
|
|
88
|
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
|
Am J Hematol
|
2014
|
0.80
|
|
89
|
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
|
Br J Haematol
|
2013
|
0.80
|
|
90
|
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
|
Br J Haematol
|
2011
|
0.80
|
|
91
|
Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders.
|
Br J Haematol
|
2004
|
0.80
|
|
92
|
Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia.
|
Am J Hematol
|
2010
|
0.80
|
|
93
|
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.
|
Br J Haematol
|
2010
|
0.80
|
|
94
|
Evidence of Rift Valley fever seroprevalence in the Sahrawi semi-nomadic pastoralist system, Western Sahara.
|
BMC Vet Res
|
2014
|
0.80
|
|
95
|
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.
|
Haematologica
|
2011
|
0.79
|
|
96
|
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia.
|
Leuk Res
|
2011
|
0.79
|
|
97
|
Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.
|
Hematol Oncol
|
2006
|
0.78
|
|
98
|
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
99
|
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia.
|
Blood
|
2010
|
0.78
|
|
100
|
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
|
Hematol Oncol
|
2011
|
0.78
|
|
101
|
Extra-osseous Ewing sarcoma of the thyroid gland mimicking lymphoma recurrence: a case report.
|
Pathol Res Pract
|
2012
|
0.77
|
|
102
|
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
|
Br J Haematol
|
2014
|
0.77
|
|
103
|
BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
|
Hematol Oncol
|
2014
|
0.77
|
|
104
|
Strategies for the transfusion of subjects with complex red cell immunisation: the Bank of rare blood donors of the Region of Lombardy.
|
Blood Transfus
|
2007
|
0.77
|
|
105
|
Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome.
|
Am J Hematol
|
2010
|
0.77
|
|
106
|
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
|
J Clin Invest
|
2015
|
0.77
|
|
107
|
Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype.
|
Hematol Oncol
|
2011
|
0.77
|
|
108
|
Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.
|
Haematologica
|
2010
|
0.76
|
|
109
|
MYC network mutations in high-risk chronic lymphocytic leukaemia.
|
Hematol Oncol
|
2014
|
0.76
|
|
110
|
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells.
|
Blood
|
2012
|
0.76
|
|
111
|
Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.
|
Br J Haematol
|
2005
|
0.76
|
|
112
|
Absence of NOTCH1 gene mutations in MALT lymphomas.
|
Br J Haematol
|
2011
|
0.76
|
|
113
|
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency.
|
Br J Haematol
|
2004
|
0.76
|
|
114
|
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
115
|
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
|
J Hematol Oncol
|
2013
|
0.76
|
|
116
|
Human herpesvirus type 8-associated primary lymphomatous effusion in an elderly HIV-negative patient: clinical and molecular characterization.
|
Ann Ital Med Int
|
2002
|
0.76
|
|
117
|
Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature.
|
Cancer Genet Cytogenet
|
2010
|
0.76
|
|
118
|
Free light-chains and renal disorders: when small is worse.
|
Lancet
|
2010
|
0.75
|
|
119
|
Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cells.
|
AIDS
|
2011
|
0.75
|
|
120
|
14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2008
|
0.75
|
|
121
|
Anaplastic large cell lymphoma and acquired angioedema: a novel association?
|
Ann Ital Med Int
|
2002
|
0.75
|
|
122
|
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.
|
Haematologica
|
2012
|
0.75
|
|
123
|
ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells.
|
Br J Haematol
|
2013
|
0.75
|
|
124
|
BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance.
|
Br J Haematol
|
2010
|
0.75
|
|
125
|
Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait.
|
Br J Haematol
|
2008
|
0.75
|
|
126
|
JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
|
Br J Haematol
|
2006
|
0.75
|
|
127
|
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2009
|
0.75
|
|
128
|
JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia.
|
Br J Haematol
|
2007
|
0.75
|
|
129
|
Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia.
|
Am J Hematol
|
2009
|
0.75
|
|
130
|
Assessment of patients with disorder of consciousness: do different Coma Recovery Scale scoring correlate with different settings?
|
J Neurol
|
2014
|
0.75
|
|
131
|
POEMS and calciphylaxis: a novel association?
|
Ann Ital Med Int
|
2005
|
0.75
|
|
132
|
rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?
|
Br J Haematol
|
2013
|
0.75
|
|
133
|
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship.
|
Dig Liver Dis
|
2011
|
0.75
|
|
134
|
Massive bowel infarction after percutaneous transluminal renal angioplasty.
|
Nephrol Dial Transplant
|
2005
|
0.75
|
|
135
|
Neuromagnetic functional coupling during dichotic listening of speech sounds.
|
Hum Brain Mapp
|
2008
|
0.75
|
|
136
|
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas.
|
Br J Haematol
|
2013
|
0.75
|
|
137
|
The Coma Recovery Scale Modified Score: a new scoring system for the Coma Recovery Scale-revised for assessment of patients with disorders of consciousness.
|
Int J Rehabil Res
|
2015
|
0.75
|